314 related articles for article (PubMed ID: 33388011)
1. Highlights on Medical Treatment of Uterine Fibroids.
Angioni S; D'Alterio MN; Daniilidis A
Curr Pharm Des; 2021; 27(36):3821-3832. PubMed ID: 33388011
[TBL] [Abstract][Full Text] [Related]
2. Current medical treatment of uterine fibroids.
Sohn GS; Cho S; Kim YM; Cho CH; Kim MR; Lee SR;
Obstet Gynecol Sci; 2018 Mar; 61(2):192-201. PubMed ID: 29564309
[TBL] [Abstract][Full Text] [Related]
3. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
4. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
5. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
6. EMAS position statement: management of uterine fibroids.
Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
[TBL] [Abstract][Full Text] [Related]
7. Uterine fibroid management: from the present to the future.
Donnez J; Dolmans MM
Hum Reprod Update; 2016 Nov; 22(6):665-686. PubMed ID: 27466209
[TBL] [Abstract][Full Text] [Related]
8. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
9. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.
Evangelisti G; Barra F; Perrone U; Di Donato N; Bogliolo S; Ceccaroni M; Ferrero S
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):441-457. PubMed ID: 35968602
[TBL] [Abstract][Full Text] [Related]
10. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
[TBL] [Abstract][Full Text] [Related]
11. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY
Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
[TBL] [Abstract][Full Text] [Related]
12. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
Donnez J; Donnez O; Dolmans MM
Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyoma: available medical treatments and new possible therapeutic options.
Islam MS; Protic O; Giannubilo SR; Toti P; Tranquilli AL; Petraglia F; Castellucci M; Ciarmela P
J Clin Endocrinol Metab; 2013 Mar; 98(3):921-34. PubMed ID: 23393173
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.
Neri M; Melis GB; Giancane E; Vallerino V; Pilloni M; Piras B; Loddo A; Paoletti AM; Mais V
Int J Womens Health; 2019; 11():535-546. PubMed ID: 31695514
[TBL] [Abstract][Full Text] [Related]
15. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
Ali M; Raslan M; Ciebiera M; Zaręba K; Al-Hendy A
Expert Opin Drug Saf; 2022 Apr; 21(4):477-486. PubMed ID: 34612122
[TBL] [Abstract][Full Text] [Related]
16. Update on medical treatment of uterine fibroids.
Faustino F; Martinho M; Reis J; Águas F
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():61-68. PubMed ID: 28732252
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors for uterine fibroids.
Song H; Lu D; Navaratnam K; Shi G
Cochrane Database Syst Rev; 2013 Oct; (10):CD009505. PubMed ID: 24151065
[TBL] [Abstract][Full Text] [Related]
18. Oral gonadotrophin-releasing hormone (GnRH) antagonists: the continuing search for the ideal nonsurgical therapy of uterine fibroids with a cautionary tale.
Sim-Ifere O; Aref-Adib M; Odejinmi F
Curr Opin Obstet Gynecol; 2023 Oct; 35(5):460-465. PubMed ID: 37560806
[TBL] [Abstract][Full Text] [Related]
19. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract][Full Text] [Related]
20. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
